Cite
HARVARD Citation
Tewari, K. et al. (n.d.). 393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. International journal of gynecological cancer. p. A162. [Online].